287192-83-0

Upstream product

• 1144-74-7 4-nitrobenzophenone 
• 58234-06-3 (4-nitrophenyl)(phenyl)methanone hydrazone 
• 99-65-0 meta-dinitrobenzene 
• 1666-17-7 benzaldehyde p-toluenesulfonylhydrazone 
• 7597-18-4 6-nitroindazole 
• 70315-70-7 3-iodo-6-nitro-1H-indazole 
• 98-80-6 phenylboronic acid 
• 34052-37-4 2-chloro-5-nitrobenzophenone 

Downstream Products

• 1204773-04-5 ethyl 2-(6-nitro-3-phenyl-1H-indazol-1-yl)thiazole-4-carboxylate 
• 1204772-11-1 ethyl 2-{6-(methylamino)-3-phenyl-1H-indazol-1-yl}thiazole-4-carboxylate 
• 1204771-90-3 C₁₇H₁₂N₄O₂S 
• 1204772-52-0 C₁₈H₁₄N₄O₂S 
• 1204771-03-8 Ethyl 2-(6-amino-3-phenyl-1H-indazol-1-yl)thiazole-4-carboxylate 
• 287192-81-8 3-phenyl-1H-indazol-6-amine 

Relevant academic research and scientific papers

Microwave assisted solvent-free C-H amination by silica-supported manganese dioxide

An effective and convenient method has been developed for the preparation of 1-unsubstituted 1H-indazoles via C-H amination of N-acetylhydrazones in the presence of a catalytic amount of manganese dioxide under microwave irradiation. This new method featured easy operation and relatively short reaction-time.

Discovery of 2-(1H-indazol-1-yl)-thiazole derivatives as selective EP 1 receptor antagonists for treatment of overactive bladder by core structure replacement

We have designed a series of potent EP1 receptor antagonists. These antagonists are a series of 2-(1H-indazol-1-yl)-thiazoles in which the core structure was replaced with pyrazole-phenyl groups. In preliminary conscious rat cystometry experiments, two representative candidates, 2 and 22, increased bladder capacity. In particular, the increase using 22 was approximately 2-fold that of the baseline. More detailed profiling of this compound and further optimization of this series promises to provide a novel class of drug for treating overactive bladder (OAB).

Synthesis of 1H-indazoles from N-tosylhydrazones and nitroaromatic compounds

A new method for the synthesis of 1H-indazoles from readily available N-tosylhydrazones and nitroaromatic compounds has been developed. This transformation occurs under transition-metal-free conditions and shows a wide substrate scope. The method has been

BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS

A nitrogen-containing bicyclic heterocyclic compound represented by the following formula (1) is provided. When the compound or a salt thereof is administered to a human being or an animal, the compound has a strong antagonistic action against EP1 recepto

Substituted bicyclic derivatives useful as anticancer agents

The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R1, R3and R4are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals with administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.